Please login to the form below

Not currently logged in
Email:
Password:

Exelixis appoints Andrew Peters to newly created position

He joins the biotech as its vice president, strategy

ExelixisCalifornia, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.

In this newly created role, Peters will work with the Exelixis leadership team to refine the company’s mid- and long-term strategy, which is focused on advancing the next generation of Exelixis medicines.

Commenting on his appointment, Michael Morrissey, president and chief executive officer of Exelixis, said: “Andrew’s extensive experience as a biotechnology industry analyst makes him a valuable addition to the Exelixis team as we work to identify potential future growth opportunities for the company.

“His familiarity with Exelixis and the biotech landscape should make for a seamless transition into his new role.”

Prior to his new role, Peters served as a director and senior analyst for Deutsche Bank Securities.

He has also held roles UBS Securities, Susquehanna International Group and Morgan Joseph & Co.

11th June 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...